Numerous combination trials with KRAS and other MAPK pathway (SHP2/MEK/ERK) inhibitors are in progress aimed at improving outcomes in patients with KRASm cancers and exploiting the presence of targetable co-alterations. The gene discussed is KRAS; the disease is cancer.